NEW YORK – It's been nearly six years since Tesha Samuels received gene therapy treatment for sickle cell disease. Samuels is ...
NEW YORK – Researchers at the University of Southern California want to assess how well members of the Hispanic community are learning about colorectal cancer and cancer genetics within an outreach ...
NEW YORK – Allarity Therapeutics on Thursday said is discontinuing a Phase II trial of its PARP inhibitor stenoparib in ovarian cancer because the treatment has shown clear clinical benefit, providing ...
NEW YORK – BridgeBio Pharma on Thursday said that its newly launched precision oncology-focused spinoff, BridgeBio Oncology Therapeutics, has completed a $200 million financing round. Already have a ...
NEW YORK – Editas Medicine on Wednesday announced a two-year extension of a collaboration with Bristol Myers Squibb to research and develop cell therapies for cancer and autoimmune diseases. Cambridge ...
NEW YORK – After successfully completing its Seagen acquisition late last year, Pfizer has ambitious plans for its oncology ...
NEW YORK – Denovo Biopharma said on Tuesday that California's Institute for Regenerative Medicine (CIRM) has awarded a $11.8 million grant to Denovo and its partners to develop the investigational ...
NEW YORK – Merck said Wednesday that its Phase III KEYNOTE-811 trial met its primary endpoint by showing that the addition of its checkpoint inhibitor Keytruda (pembrolizumab) to Genentech's anti-HER2 ...
The firm's gene-editing therapy PM359 is designed to correct a specific variant in the NCF1 gene, which can cause the rare ...
NEW YORK – Repare Therapeutics and Debiopharm on Tuesday said they dosed the first patient with the PKMYT1 inhibitor lunresertib and the WEE1 kinase inhibitor Debio 0123 in a new arm of Repare's ...
Annovis Bio Planning New Drug Trial in Biomarker-Defined Alzheimer's Group After Mixed Study Readout
The company's stock dropped more than 60 percent on the release of the Phase II/III data on buntanetap, which included a missed primary endpoint.
The Phase II portion of the Phase I/II trial is evaluating INB-400 and maintenance chemotherapy in newly diagnosed glioblastoma patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results